Mostrar el registro sencillo del ítem

dc.contributor.authorRestrepo Valencia, Cesar A.
dc.contributor.authorAguirre Arango, Jose V.
dc.contributor.authorMusso, Carlos G.
dc.date.accessioned2020-01-17T14:39:23Z
dc.date.available2020-01-17T14:39:23Z
dc.date.issued2019
dc.identifier.issn11787058
dc.identifier.urihttps://hdl.handle.net/20.500.12442/4533
dc.description.abstractIn a high percentage of patients with chronic kidney disease (CKD) low levels of vitamin D are detected. The purpose of this study was to evaluate if the native vitamin D therapy (cholecalciferol) in the patients with stage 3 and hypovitaminosis D allows to modify markers of bone and mineral metabolism once normal serum levels have been achieved.eng
dc.format.mimetypepdfspa
dc.language.isoengeng
dc.publisherDovepresseng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionaleng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/eng
dc.sourceInternational Journal of Nephrology and Renovascular Diseaseeng
dc.sourceVol. 12 (2019)
dc.source.urihttps://doi.org/10.2147/IJNRD.S214194
dc.subjectVitamin Deng
dc.subjectCholecalciferoleng
dc.subjectChronic kidney diseaseeng
dc.subjectHypovitaminosis Deng
dc.titleEffectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South Americaeng
dc.typearticleeng
dcterms.referencesDusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8–F28. doi:10.1152/ajprenal.00336.2004eng
dcterms.referencesJones G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu Rev Nutr. 2013;33:10.1–10.22. doi:10.1146/annurev-nutr-071812-161203eng
dcterms.referencesMichigami T. Update on recent progress in vitamin D research. Vitamin D metabolism and its regulation. Clin Calcium. 2017;27:1517–1523. doi:10.CliCa171115171523eng
dcterms.referencesWheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. doi:10.1016/j.kisu.2017.04.001eng
dcterms.referencesRestrepo VCA, Aguirre AJV. Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2–5. Colomb Med (Cali). 2016;47: 160–166. doi:10.25100/cm.v47i3.2148eng
dcterms.referencesRestrepo VCA, Aguirre AJV, Caceres ED. Determination of vitamin D (25(OH)D) levels in renal transplant patients and their importance in accordance with the glomerular filtration rate. Rev Colomb Reumatol. 2018;25:161–168.eng
dcterms.referencesGluba-Brzozka A, Franczyk B, Cialkowska-Rysz C, Olszewski R, Rysz J. Impact of vitamin D on the cardiovascular system in advance chronic kidney disease (CKD) and dialysis patients. Nutrients. 2018;10:6: 709. doi:10.3390/nu10060709eng
dcterms.referencesZhang Y, Darssan D, Pascoe EM, Johnson DW, Pi H, Dong J. Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. Nephrol Dial Transplant. 2018;33:1742–1751. doi:10.1093/ndt/gfy016eng
dcterms.referencesLiu M, Wang J, He Y. Serum 25-Hydroxyvitamin D were associated with higher risk of both albuminuria and impaired GFR incidence: a cohort study based on CLHLS study. BMC Nephrol. 2019;20:20. doi:10.1186/s12882-019-1202-8eng
dcterms.referencesMolina P, Gorriz JL, Molina MD, et al. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol. 2016;5:471–481. doi:10.5527/wjn.v5.i5.471eng
dcterms.referencesEknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202. doi:10.1016/S0272- 6386(03)00905-3eng
dcterms.referencesKDIGO. Clinical practice for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD). Kidney Int. 2009;76(suppl 113):S1–S130.eng
dcterms.referencesAlola JF. Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab. 2011;96:2987–2996. doi:10.1210/jc.2011-0090eng
dcterms.referencesVieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–856. doi:10.1093/ajcn/ 69.5.842eng
dcterms.referencesLee JP, Tansey M, Jetton JG, Krasowski MD. Vitamina D toxicity: a 16 year retrospective study at an academic medical center. Lab Med. 2018;21:123–129. doi:10.1093/labmed/lmx077eng
dcterms.referencesEtayo HE, Restrepo CA. Acute tubular necrosis due to hypercalcemia secondary to vitamin D toxicity. Acta Med Colomb. 2010;35:99–102.eng
dcterms.referencesGarcia CA, Holguin MC, Caceres D, Restrepo CA. Importance of hyperphosphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev Colomb Nefrol. 2017;4:24–41.eng
dcterms.referencesNordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67:929–936. doi:10.1210/jcem-67-5-929eng
dcterms.referencesToussaint ND, Damasiewicz MJ. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the arms? Nephrology (Carlton). 2017;22 (Suppl 2):51–56. doi:10.1111/nep.13026eng
dcterms.referencesLevey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. doi:10.7326/0003-4819-145-4-200608150-00004eng
dcterms.referencesDawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716. doi:10.1007/s00198-005-1867-7eng
dcterms.referencesDawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–1154. doi:10.1007/s00198-010-1285-3eng
dcterms.referencesAmerican geriatrics society workgroup on vitamin D supplementation for older adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for prevention of falls and their consequences. J Am Geriatr Soc. 2014;62:147–152. doi:10.1111/jgs.12631eng
dcterms.referencesLips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol. 2007;103:620–625. doi:10.1016/j.jsbmb.2006.12.076eng
dcterms.referencesFuleihan GE-H. Vitamin D deficiency in the Middle East and its health consequences for children and Adults. Clinic Rev Bone Miner Metab. 2009;7:77–93. doi:10.1007/s12018-009-9027-9eng
dcterms.referencesMithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20: 1807–1820. doi:10.1007/s00198-009-0954-6eng
dcterms.referencesHolick MF, Binkley NC, Bischoff-Ferrari HA, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930. doi:10.1210/jc.2011- 0385eng
dcterms.referencesChapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439–443. doi:10.1007/s001980050030eng
dcterms.referencesVieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88:185–191. doi:10.1210/jc.2002- 021064eng
dcterms.referencesDawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997;65:67–71. doi:10.1093/ajcn/ 65.1.67eng
dcterms.referencesRoss AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58. doi:10.1210/jc.2010-2704eng
dcterms.referencesPriemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305–312. doi:10.1359/jbmr. 090728eng
dcterms.referencesShroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease stages 2–5 and on dialysis. European society for paediatric nephrology chronic kidney disease mineral and bone disorders and dialysis working groups. Nephrol Dial Transplant. 2017;32: 1098–1113. doi:10.1093/ndt/gfx065eng
dcterms.referencesShroff R, Wan M, Gullett A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol. 2012;7:216–223. doi:10.2215/CJN.04760511eng
dcterms.referencesKrause R, Roth HJ, Kaase H, Stange R, Holick MF. Vitamin D status in chronic kidney disease – UVB irradiation is superior to oral supplementation. Anticancer Res. 2016;36:1397–1401.eng
dcterms.referencesKDOQI WG. K/DOQI clinical practice guidelines for nutrition in children with CKD. Am J Kidney Dis. 2009;53:S11–S104.eng
dcterms.referencesFried C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2017;10:109–122. doi:10.2147/IJNRD. S97637eng
dcterms.referencesAlvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672–679. doi:10.3945/ajcn.112.040642eng
dcterms.referencesWesterberg P-A, Sterner G, Ljunggren O, et al. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3–4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant. 2018;33:466–471. doi:10.1093/ ndt/gfx059eng
dcterms.referencesYadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease. J Bone Miner Res. 2018;33:404–409. doi:10.1002/jbmr.v33.3eng
dcterms.referencesAl-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50:59–68. doi:10.1053/j.ajkd.2007.04.010eng
dcterms.referencesZisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27:36–43. doi:10.1159/000098561eng
dcterms.referencesThimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of high vs conventional ergocalciferol dose for increasing 25- hydroxyvitamin D and suppressing parathyroid hormone levels in stage III–IV CKD with vitamin D deficiency/insufficiency: a randomized controlled trial. J Med Assoc Thai. 2015;98:643–648.eng
dcterms.referencesTripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systemic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–1364. doi:10.3945/ajcn.111.031070eng
dcterms.referencesWetmore JB, Kimber C, Mahnken JD, Stubbs JR. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Br J Nutr. 2016;116:2074–2081. doi:10.1017/S000711451600427Xeng
dcterms.referencesTripkovic L, Wilson LR, Hart K, et al. Daily supplementation with 15 ug vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12 wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr. 2017;106:481–490. doi:10. 3945/ajcn.116.138693eng
dcterms.referencesOliveri B, Mastaglia SR, Brito GM, et al. Vitamin D3 seems more appropiate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. Eur J Clin Nutr. 2015;69:697–702. doi:10.1038/ejcn.2015.16eng
dcterms.referencesChao YS, Brunel L, Faris P, Veugelers PJ. The importance of dose, frequency and duration of vitamin D supplementation for plasma 25-hydroxyvitamin D. Nutrients. 2013;5:4067–4078. doi:10.3390/ nu5104067eng
dcterms.referencesMager D, Jackson ST, Hoffmann M, Jindal K, Senior PA. Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: results of an open label randomized clinical trial. Clin Nutr. 2017;36:686–696. doi:10.1016/j.clnu.2016. 05.012eng
dcterms.referencesBover J, Egido J, Fernandez-Giraldez E, et al. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. Nefrologia. 2015;35:28–41. doi:10.3265/ Nefrologia.pre2014.Sep.11796eng
dcterms.referencesMelamed ML, Chonchol M, Gutierre OM, et al. The role of vitamin D in CKD stages 3 to 4: report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis. 2018;72:834–845. doi:10.1053/j.ajkd.2018.06.031eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos
    Artículos científicos evaluados por pares

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional